Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term breathing problems and poor airflow The main symptoms include shortness of breath and cough with sputum production. COPD is a progressive disease, meaning it typically worsens over time. Eventually everyday activities, such as walking or getting dressed, become difficult .Chronic bronchitis and emphysema are older terms used for different types of COPD.
The “Chronic Obstructive Pulmonary Disease Industry Forecast” looks at past sales and reviews total world Chronic Obstructive Pulmonary Disease sales in 2022, providing a comprehensive analysis by region and market sector of projected Chronic Obstructive Pulmonary Disease sales for 2023 through 2029. With Chronic Obstructive Pulmonary Disease sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Chronic Obstructive Pulmonary Disease industry.
This Insight Report provides a comprehensive analysis of the global Chronic Obstructive Pulmonary Disease landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Chronic Obstructive Pulmonary Disease portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Chronic Obstructive Pulmonary Disease market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Chronic Obstructive Pulmonary Disease and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Chronic Obstructive Pulmonary Disease.
The global Chronic Obstructive Pulmonary Disease market size is projected to grow from US$ 3911.3 million in 2022 to US$ 4733.9 million in 2029; it is expected to grow at a CAGR of 2.8% from 2023 to 2029.
Globally the market for COPD is increasing rapidly. The major factor that derives the growth of COPD is the increasing growth in smoking in adults. Furthermore increasing pollution in the environment and increasing asthma patients are increasing the growth of COPD market.
This report presents a comprehensive overview, market shares, and growth opportunities of Chronic Obstructive Pulmonary Disease market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Bronchodilators
Glucocorticoids
Other
Segmentation by application
Prevention
Diagnostic
Treatment
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
GSK
MSD
Sunovion
Novartis
Roche Group
Pfizer
Jubilant Pharma Limited
Almirall
Horizon Pharma
Boehringer Ingelheim
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Chronic Obstructive Pulmonary Disease Market Size 2018-2029
2.1.2 Chronic Obstructive Pulmonary Disease Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Chronic Obstructive Pulmonary Disease Segment by Type
2.2.1 Bronchodilators
2.2.2 Glucocorticoids
2.2.3 Other
2.3 Chronic Obstructive Pulmonary Disease Market Size by Type
2.3.1 Chronic Obstructive Pulmonary Disease Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Chronic Obstructive Pulmonary Disease Market Size Market Share by Type (2018-2023)
2.4 Chronic Obstructive Pulmonary Disease Segment by Application
2.4.1 Prevention
2.4.2 Diagnostic
2.4.3 Treatment
2.5 Chronic Obstructive Pulmonary Disease Market Size by Application
2.5.1 Chronic Obstructive Pulmonary Disease Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Chronic Obstructive Pulmonary Disease Market Size Market Share by Application (2018-2023)
3 Chronic Obstructive Pulmonary Disease Market Size by Player
3.1 Chronic Obstructive Pulmonary Disease Market Size Market Share by Players
3.1.1 Global Chronic Obstructive Pulmonary Disease Revenue by Players (2018-2023)
3.1.2 Global Chronic Obstructive Pulmonary Disease Revenue Market Share by Players (2018-2023)
3.2 Global Chronic Obstructive Pulmonary Disease Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Chronic Obstructive Pulmonary Disease by Regions
4.1 Chronic Obstructive Pulmonary Disease Market Size by Regions (2018-2023)
4.2 Americas Chronic Obstructive Pulmonary Disease Market Size Growth (2018-2023)
4.3 APAC Chronic Obstructive Pulmonary Disease Market Size Growth (2018-2023)
4.4 Europe Chronic Obstructive Pulmonary Disease Market Size Growth (2018-2023)
4.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Market Size Growth (2018-2023)
5 Americas
5.1 Americas Chronic Obstructive Pulmonary Disease Market Size by Country (2018-2023)
5.2 Americas Chronic Obstructive Pulmonary Disease Market Size by Type (2018-2023)
5.3 Americas Chronic Obstructive Pulmonary Disease Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Chronic Obstructive Pulmonary Disease Market Size by Region (2018-2023)
6.2 APAC Chronic Obstructive Pulmonary Disease Market Size by Type (2018-2023)
6.3 APAC Chronic Obstructive Pulmonary Disease Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Chronic Obstructive Pulmonary Disease by Country (2018-2023)
7.2 Europe Chronic Obstructive Pulmonary Disease Market Size by Type (2018-2023)
7.3 Europe Chronic Obstructive Pulmonary Disease Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Chronic Obstructive Pulmonary Disease by Region (2018-2023)
8.2 Middle East & Africa Chronic Obstructive Pulmonary Disease Market Size by Type (2018-2023)
8.3 Middle East & Africa Chronic Obstructive Pulmonary Disease Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Chronic Obstructive Pulmonary Disease Market Forecast
10.1 Global Chronic Obstructive Pulmonary Disease Forecast by Regions (2024-2029)
10.1.1 Global Chronic Obstructive Pulmonary Disease Forecast by Regions (2024-2029)
10.1.2 Americas Chronic Obstructive Pulmonary Disease Forecast
10.1.3 APAC Chronic Obstructive Pulmonary Disease Forecast
10.1.4 Europe Chronic Obstructive Pulmonary Disease Forecast
10.1.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Forecast
10.2 Americas Chronic Obstructive Pulmonary Disease Forecast by Country (2024-2029)
10.2.1 United States Chronic Obstructive Pulmonary Disease Market Forecast
10.2.2 Canada Chronic Obstructive Pulmonary Disease Market Forecast
10.2.3 Mexico Chronic Obstructive Pulmonary Disease Market Forecast
10.2.4 Brazil Chronic Obstructive Pulmonary Disease Market Forecast
10.3 APAC Chronic Obstructive Pulmonary Disease Forecast by Region (2024-2029)
10.3.1 China Chronic Obstructive Pulmonary Disease Market Forecast
10.3.2 Japan Chronic Obstructive Pulmonary Disease Market Forecast
10.3.3 Korea Chronic Obstructive Pulmonary Disease Market Forecast
10.3.4 Southeast Asia Chronic Obstructive Pulmonary Disease Market Forecast
10.3.5 India Chronic Obstructive Pulmonary Disease Market Forecast
10.3.6 Australia Chronic Obstructive Pulmonary Disease Market Forecast
10.4 Europe Chronic Obstructive Pulmonary Disease Forecast by Country (2024-2029)
10.4.1 Germany Chronic Obstructive Pulmonary Disease Market Forecast
10.4.2 France Chronic Obstructive Pulmonary Disease Market Forecast
10.4.3 UK Chronic Obstructive Pulmonary Disease Market Forecast
10.4.4 Italy Chronic Obstructive Pulmonary Disease Market Forecast
10.4.5 Russia Chronic Obstructive Pulmonary Disease Market Forecast
10.5 Middle East & Africa Chronic Obstructive Pulmonary Disease Forecast by Region (2024-2029)
10.5.1 Egypt Chronic Obstructive Pulmonary Disease Market Forecast
10.5.2 South Africa Chronic Obstructive Pulmonary Disease Market Forecast
10.5.3 Israel Chronic Obstructive Pulmonary Disease Market Forecast
10.5.4 Turkey Chronic Obstructive Pulmonary Disease Market Forecast
10.5.5 GCC Countries Chronic Obstructive Pulmonary Disease Market Forecast
10.6 Global Chronic Obstructive Pulmonary Disease Forecast by Type (2024-2029)
10.7 Global Chronic Obstructive Pulmonary Disease Forecast by Application (2024-2029)
11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Chronic Obstructive Pulmonary Disease Product Offered
11.1.3 AstraZeneca Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 GSK
11.2.1 GSK Company Information
11.2.2 GSK Chronic Obstructive Pulmonary Disease Product Offered
11.2.3 GSK Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 GSK Main Business Overview
11.2.5 GSK Latest Developments
11.3 MSD
11.3.1 MSD Company Information
11.3.2 MSD Chronic Obstructive Pulmonary Disease Product Offered
11.3.3 MSD Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 MSD Main Business Overview
11.3.5 MSD Latest Developments
11.4 Sunovion
11.4.1 Sunovion Company Information
11.4.2 Sunovion Chronic Obstructive Pulmonary Disease Product Offered
11.4.3 Sunovion Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Sunovion Main Business Overview
11.4.5 Sunovion Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Chronic Obstructive Pulmonary Disease Product Offered
11.5.3 Novartis Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Roche Group
11.6.1 Roche Group Company Information
11.6.2 Roche Group Chronic Obstructive Pulmonary Disease Product Offered
11.6.3 Roche Group Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Roche Group Main Business Overview
11.6.5 Roche Group Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Chronic Obstructive Pulmonary Disease Product Offered
11.7.3 Pfizer Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Jubilant Pharma Limited
11.8.1 Jubilant Pharma Limited Company Information
11.8.2 Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Product Offered
11.8.3 Jubilant Pharma Limited Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Jubilant Pharma Limited Main Business Overview
11.8.5 Jubilant Pharma Limited Latest Developments
11.9 Almirall
11.9.1 Almirall Company Information
11.9.2 Almirall Chronic Obstructive Pulmonary Disease Product Offered
11.9.3 Almirall Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Almirall Main Business Overview
11.9.5 Almirall Latest Developments
11.10 Horizon Pharma
11.10.1 Horizon Pharma Company Information
11.10.2 Horizon Pharma Chronic Obstructive Pulmonary Disease Product Offered
11.10.3 Horizon Pharma Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Horizon Pharma Main Business Overview
11.10.5 Horizon Pharma Latest Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Company Information
11.11.2 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Product Offered
11.11.3 Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Boehringer Ingelheim Main Business Overview
11.11.5 Boehringer Ingelheim Latest Developments
12 Research Findings and Conclusion
*If Applicable.